Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Tiede

Showing results (11-20 of 121) with videos related to

Pageof 13
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 2, 2024
Andreas Tiede, Sophie Susen, Ton Lisman
Annals of Hematology|July 5, 2020
Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational studyChristiane Dobbelstein, Georgios Leandros Moschovakis, Andreas Tiede
Journal of Thrombosis and Haemostasis : JTH|December 11, 2020
Should emicizumab be used in patients with acquired hemophilia A?Andreas Tiede, Bettina Kemkes-Matthes, Paul Knöbl
Seminars in Thrombosis and Hemostasis|October 10, 2014
Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challengesAndreas Tiede, Sonja Werwitzke, Rüdiger E Scharf
Deutsches Arzteblatt International|December 5, 2022
Gene Therapy for Hemophilia-Opportunities and RisksWolfgang Miesbach, Robert Klamroth, Johannes Oldenburg, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 23, 2021
Clinical outcomes after joint surgery in patients on turoctocog alfa pegol (N8-GP) prophylaxis: A post hoc analysisKingsley Hampton, Andreas Tiede, Shwetha Shivamurthy, et al.
Current Medical Research and Opinion|August 31, 2019
Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapyJohannes Oldenburg, Songkai Yan, Geraldine Maro, et al.
Blood|May 11, 2011
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia BClaude Negrier, Karin Knobe, Andreas Tiede, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 30, 2021
Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysersCarolin Ketteler, Ingrid Hoffmann, Simon Davidson, et al.
Thrombosis and Haemostasis|May 12, 2017
CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitroNadine Vollack, Julia Friese, Sabine Bergmann, et al.
Pageof 13

Showing results (11-20 of 121) with videos related to

Sort By:
Pageof 13
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 2, 2024
Andreas Tiede, Sophie Susen, Ton Lisman
Annals of Hematology|July 5, 2020
Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational studyChristiane Dobbelstein, Georgios Leandros Moschovakis, Andreas Tiede
Journal of Thrombosis and Haemostasis : JTH|December 11, 2020
Should emicizumab be used in patients with acquired hemophilia A?Andreas Tiede, Bettina Kemkes-Matthes, Paul Knöbl
Seminars in Thrombosis and Hemostasis|October 10, 2014
Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challengesAndreas Tiede, Sonja Werwitzke, Rüdiger E Scharf
Deutsches Arzteblatt International|December 5, 2022
Gene Therapy for Hemophilia-Opportunities and RisksWolfgang Miesbach, Robert Klamroth, Johannes Oldenburg, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 23, 2021
Clinical outcomes after joint surgery in patients on turoctocog alfa pegol (N8-GP) prophylaxis: A post hoc analysisKingsley Hampton, Andreas Tiede, Shwetha Shivamurthy, et al.
Current Medical Research and Opinion|August 31, 2019
Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapyJohannes Oldenburg, Songkai Yan, Geraldine Maro, et al.
Blood|May 11, 2011
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia BClaude Negrier, Karin Knobe, Andreas Tiede, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 30, 2021
Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysersCarolin Ketteler, Ingrid Hoffmann, Simon Davidson, et al.
Thrombosis and Haemostasis|May 12, 2017
CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitroNadine Vollack, Julia Friese, Sabine Bergmann, et al.
Pageof 13